Bin Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bin Yu has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Hangtian Wu
Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 shared publications- Xianrong Zhang
Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 shared publications - Peisheng Chen
Department of Orthopedics, Fuzhou Second General Hospital, School of Clinical Medicine, Fujian Medical University, Fujian Provincial Clinical Medical Research Center for First Aid and Rehabilitation in Orthopedic Trauma, Fuzhou, 350007, Fujian, People's Republic of China
5 shared publications Ganming Deng
Department of Orthopaedics and Traumatology Nanfang Hospital, Southern Medical University Guangzhou People's Republic of China
4 shared publicationsLei Wang
Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, China
4 shared publications- Yanjun Hu
Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, China
4 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Elsevier in Chinese Journal of Traumatology
- Vol. 29 (5) , 313-326
Chinese expert consensus on tetanus prophylaxis in major trauma (2026 Edition)
- 24 August 2026
- Published by Elsevier in Chinese Journal of Traumatology
- Vol. 29 (5) , 313-326
Open AccessChinese expert consensus on tetanus prophylaxis in major trauma (2026 Edition)
- Open Access
- 13 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115175
Hairyvein agrimony-derived nanovesicles in microneedles eradicate intracellular bacteria and reverse senescence to heal diabetic foot osteomyelitis
- 13 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115175
Open AccessHairyvein agrimony-derived nanovesicles in microneedles eradicate intracellular bacteria and reverse senescence to heal diabetic foot osteomyelitis
- 15 October 2025
- Vol. 39 (10) , 1342-1350
[Recent advances regarding diagnosis and treatment of fracture-related infection].
To review the current research status on the diagnosis and treatment of fracture-related infection (FRI). The research literature in the field of FRI both domestically and internationally in recent years were widely reviewed, and the research progress of FRI from the aspects of definition and classification, epidemiological characteristics, diagnosis and treatment elaborated, in order to provide reference for clinical practices. In recent years, specific classifications for FRI have gradually emerged. FRI is characterized by high incidence, high recurrence, high disability rates, and significant economic costs. Key diagnostic points include clinical signs and symptoms, imaging tests, serological biomarkers, pathogen identification, and histopathological examination. Treatment principles encompass debridement, management of implants (retention or removal), systemic and local antibiotic use, reconstruction of bone and soft tissue defects, and functional and psychological rehabilitation. Although FRI is a catastrophic complication following limb bone trauma, early precise diagnosis and standardized treatment are key to improving cure rates, reducing recurrence, and enhancing patients' quality of life.
- 15 October 2025
- Vol. 39 (10) , 1342-1350
[Recent advances regarding diagnosis and treatment of fracture-related infection].
To review the current research status on the diagnosis and treatment of fracture-related infection (FRI). The research literature in the field of FRI both domestically and internationally in recent years were widely reviewed, and the research progress of FRI from the aspects of definition and classification, epidemiological characteristics, diagnosis and treatment elaborated, in order to provide reference for clinical practices. In recent years, specific classifications for FRI have gradually emerged. FRI is characterized by high incidence, high recurrence, high disability rates, and significant economic costs. Key diagnostic points include clinical signs and symptoms, imaging tests, serological biomarkers, pathogen identification, and histopathological examination. Treatment principles encompass debridement, management of implants (retention or removal), systemic and local antibiotic use, reconstruction of bone and soft tissue defects, and functional and psychological rehabilitation. Although FRI is a catastrophic complication following limb bone trauma, early precise diagnosis and standardized treatment are key to improving cure rates, reducing recurrence, and enhancing patients' quality of life.
- Open Access
- 5 November 2024
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 49, 325-338
Sensory nerve EP4 facilitates heterotopic ossification by regulating angiogenesis-coupled bone formation
- 5 November 2024
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 49, 325-338
Open AccessSensory nerve EP4 facilitates heterotopic ossification by regulating angiogenesis-coupled bone formation
- Open Access
- 8 April 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (5) , 991-1004
Systematic Review of Heel Puncture-Related Osteomyelitis of the Calcaneus in Newborn Infants
Introduction Heel puncture (HP) in neonates can result in osteomyelitis if done non-aseptically or with incorrect technique. This study summarizes clinical experience with heel puncture-related osteomyelitis of the calcaneus (HP-CO) in newborns. Methods We systematically reviewed studies that examined HP-CO in newborn patients using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search included the PubMed, Embase, and Cochrane Library databases until December 31, 2023. We used the National Institutes of Health (NIH) assessment scale to evaluate the quality of our analyzed studies. Results This study analyzed 15 neonatal calcaneal osteomyelitis (CO) cases due to HP conducted in six countries from 1976 to 2016. The average age of the cases was 8.87 ± 6.13 days, with an average birth weight of 2367.27 ± 947.59 g. The infants had undergone an average of 9.00 ± 8.90 HP, with 93.33% exhibiting swelling. Staphylococcus aureus was present in 80% of cases. Beta-lactam antibiotics were used, with satisfactory outcomes in 53.33% of cases. However, in seven cases, three patients had flatfoot due to calcaneal deformity, and other complications were observed in some patients after 7–8 years. Conclusions This study offers valuable insights into a rare condition, including its epidemiology, clinical and laboratory characteristics, and treatment options for infants with HP-CO. To prevent the risk of osteomyelitis in this vulnerable group of patients, increasing awareness and maintaining strict aseptic techniques is necessary. We recommend that infants presenting with tenderness, redness, purulent discharge, erythema, or fever and with a history of repeated HP and swollen ankles should be evaluated for suspicion of osteomyelitis. A graphical abstract is avilable for this article. Graphical Abstract
- 8 April 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (5) , 991-1004
Open AccessSystematic Review of Heel Puncture-Related Osteomyelitis of the Calcaneus in Newborn Infants
Introduction Heel puncture (HP) in neonates can result in osteomyelitis if done non-aseptically or with incorrect technique. This study summarizes clinical experience with heel puncture-related osteomyelitis of the calcaneus (HP-CO) in newborns. Methods We systematically reviewed studies that examined HP-CO in newborn patients using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search included the PubMed, Embase, and Cochrane Library databases until December 31, 2023. We used the National Institutes of Health (NIH) assessment scale to evaluate the quality of our analyzed studies. Results This study analyzed 15 neonatal calcaneal osteomyelitis (CO) cases due to HP conducted in six countries from 1976 to 2016. The average age of the cases was 8.87 ± 6.13 days, with an average birth weight of 2367.27 ± 947.59 g. The infants had undergone an average of 9.00 ± 8.90 HP, with 93.33% exhibiting swelling. Staphylococcus aureus was present in 80% of cases. Beta-lactam antibiotics were used, with satisfactory outcomes in 53.33% of cases. However, in seven cases, three patients had flatfoot due to calcaneal deformity, and other complications were observed in some patients after 7–8 years. Conclusions This study offers valuable insights into a rare condition, including its epidemiology, clinical and laboratory characteristics, and treatment options for infants with HP-CO. To prevent the risk of osteomyelitis in this vulnerable group of patients, increasing awareness and maintaining strict aseptic techniques is necessary. We recommend that infants presenting with tenderness, redness, purulent discharge, erythema, or fever and with a history of repeated HP and swollen ankles should be evaluated for suspicion of osteomyelitis. A graphical abstract is avilable for this article. Graphical Abstract
- Open Access
- 27 July 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 169, 209-227
In situ sprayed hydrogels containing resiquimod-loaded liposomes reduce chronic osteomyelitis recurrence by intracellular bacteria clearance
- 27 July 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 169, 209-227
Open AccessIn situ sprayed hydrogels containing resiquimod-loaded liposomes reduce chronic osteomyelitis recurrence by intracellular bacteria clearance
- Open Access
- 1 July 2023
- Published by KEAI Publishing in Bioactive Materials
- Vol. 25, 273-290
Triple-functional bone adhesive with enhanced internal fixation, bacteriostasis and osteoinductive properties for open fracture repair
At present, effective fixation and anti-infection implant materials represent the mainstay for the treatment of open fractures. However, external fixation can cause nail tract infections and is ineffective for fixing small fracture fragments. Moreover, closed reduction and internal fixation during the early stage of injury can lead to potential bone infection, conducive to bone nonunion and delayed healing. Herein, we designed a bone adhesive with anti-infection, osteogenic and bone adhesion fixation properties to promote reduction and fixation of open fractures and subsequent soft tissue repair. It was prepared by the reaction of gelatin (Gel) and oxidized starch (OS) with vancomycin (VAN)-loaded mesoporous bioactive glass nanoparticles (MBGNs) covalently cross-linked with Schiff bases. Characterization and adhesion experiments were conducted to validate the successful preparation of the Gel-OS/VAN@MBGNs (GOVM-gel) adhesive. Meanwhile, in vitro cell experiments demonstrated its good antibacterial effects with the ability to stimulate bone marrow mesenchymal stem cell (BMSCs) proliferation, upregulate the expression of alkaline phosphatase (ALP) and osteogenic proteins (RunX2 and OPN) and enhance the deposition of calcium nodules. Additionally, we established a rat skull fracture model and a subcutaneous infection model. The histological analysis showed that bone adhesive enhanced osteogenesis, and in vivo experiments demonstrated that the number of inflammatory cells and bacteria was significantly reduced. Overall, the adhesive could promote early reduction of fractures and antibacterial and osteogenic effects, providing the foothold for treatment of this patient population.
- 1 July 2023
- Published by KEAI Publishing in Bioactive Materials
- Vol. 25, 273-290
Open AccessTriple-functional bone adhesive with enhanced internal fixation, bacteriostasis and osteoinductive properties for open fracture repair
At present, effective fixation and anti-infection implant materials represent the mainstay for the treatment of open fractures. However, external fixation can cause nail tract infections and is ineffective for fixing small fracture fragments. Moreover, closed reduction and internal fixation during the early stage of injury can lead to potential bone infection, conducive to bone nonunion and delayed healing. Herein, we designed a bone adhesive with anti-infection, osteogenic and bone adhesion fixation properties to promote reduction and fixation of open fractures and subsequent soft tissue repair. It was prepared by the reaction of gelatin (Gel) and oxidized starch (OS) with vancomycin (VAN)-loaded mesoporous bioactive glass nanoparticles (MBGNs) covalently cross-linked with Schiff bases. Characterization and adhesion experiments were conducted to validate the successful preparation of the Gel-OS/VAN@MBGNs (GOVM-gel) adhesive. Meanwhile, in vitro cell experiments demonstrated its good antibacterial effects with the ability to stimulate bone marrow mesenchymal stem cell (BMSCs) proliferation, upregulate the expression of alkaline phosphatase (ALP) and osteogenic proteins (RunX2 and OPN) and enhance the deposition of calcium nodules. Additionally, we established a rat skull fracture model and a subcutaneous infection model. The histological analysis showed that bone adhesive enhanced osteogenesis, and in vivo experiments demonstrated that the number of inflammatory cells and bacteria was significantly reduced. Overall, the adhesive could promote early reduction of fractures and antibacterial and osteogenic effects, providing the foothold for treatment of this patient population.
- Open Access
- 13 February 2023
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 49 (3) , 1561-1575
Prospective randomized multicenter noninferiority clinical trial evaluating the use of TFN-advancedTM proximal femoral nailing system (TFNA) for the treatment of proximal femur fracture in a Chinese population
Purpose: To evaluate whether the 24-weeks postoperative fracture union rate for the investigational TFNA intramedullary nail was non-inferior compared to the control product PFNA-II. Methods: The study was a prospective, randomized, single-blind, noninferiority dual-arm study drawing from 9 trauma centers across China, between November 2018 and September 2020, with follow-up measurements at 24 weeks after internal fixation. The full analysis data set (FAS [Intent-to-Treat]) was analyzed and is summarized here. The primary outcome was fracture union rate, a composite score combining clinical and radiographic assessment. Secondary endpoints comprised (a) clinical outcomes including (1) SF-12, (2) Harris Hip, and (3) EQ-5D Scores, (b) radiographic incidence of complications such as loosening or cut-out requiring revision, (c) revision rates, (d) reoperation rates, and (e) adverse events, including 24-weeks revision and reoperation rates. Results: Both TFNA and PFNA-II group fracture healing rates were 100% at 24 weeks; TFNA was therefore shown to be non-inferior to PFNA-II. With baseline data matched in all parameters except age in both the TFNA and PFNA-II groups, comparisons of union rates, SF-12, Harris Hip, and EQ-5D Scores yielded p values > 0.05 indicating no significant difference between the two groups, further supporting the noninferiority of TFNA. In both groups, revision and re-operation rates were 0, and the incidences of serious adverse events were 19.4% and 17.4%, respectively. Conclusion: In terms of fracture union rate at 24 weeks, the DePuy Synthes Trochanteric Fixation Nail Advanced (TFNA) was not inferior to the marketed Proximal Femoral Nail Antirotation (PFNA-II) device produced by the same manufacturer. Secondary and safety outcomes showed no significant differences between the two groups. Registration: Registration was completed at ClinicalTrials.gov NCT03635320.
- 13 February 2023
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 49 (3) , 1561-1575
Open AccessProspective randomized multicenter noninferiority clinical trial evaluating the use of TFN-advancedTM proximal femoral nailing system (TFNA) for the treatment of proximal femur fracture in a Chinese population
Purpose: To evaluate whether the 24-weeks postoperative fracture union rate for the investigational TFNA intramedullary nail was non-inferior compared to the control product PFNA-II. Methods: The study was a prospective, randomized, single-blind, noninferiority dual-arm study drawing from 9 trauma centers across China, between November 2018 and September 2020, with follow-up measurements at 24 weeks after internal fixation. The full analysis data set (FAS [Intent-to-Treat]) was analyzed and is summarized here. The primary outcome was fracture union rate, a composite score combining clinical and radiographic assessment. Secondary endpoints comprised (a) clinical outcomes including (1) SF-12, (2) Harris Hip, and (3) EQ-5D Scores, (b) radiographic incidence of complications such as loosening or cut-out requiring revision, (c) revision rates, (d) reoperation rates, and (e) adverse events, including 24-weeks revision and reoperation rates. Results: Both TFNA and PFNA-II group fracture healing rates were 100% at 24 weeks; TFNA was therefore shown to be non-inferior to PFNA-II. With baseline data matched in all parameters except age in both the TFNA and PFNA-II groups, comparisons of union rates, SF-12, Harris Hip, and EQ-5D Scores yielded p values > 0.05 indicating no significant difference between the two groups, further supporting the noninferiority of TFNA. In both groups, revision and re-operation rates were 0, and the incidences of serious adverse events were 19.4% and 17.4%, respectively. Conclusion: In terms of fracture union rate at 24 weeks, the DePuy Synthes Trochanteric Fixation Nail Advanced (TFNA) was not inferior to the marketed Proximal Femoral Nail Antirotation (PFNA-II) device produced by the same manufacturer. Secondary and safety outcomes showed no significant differences between the two groups. Registration: Registration was completed at ClinicalTrials.gov NCT03635320.
- 30 April 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (11) , 7342-7355
Nkx2‐3 induces autophagy inhibiting proliferation and migration of vascular smooth muscle cells via AMPK/mTOR signaling pathway
Vascular remodeling and restenosis are common complications after percutaneous coronary intervention. Excessive proliferation and migration of vascular smooth muscle cells (VSMCs) play important roles in intimal hyperplasia‐induced vascular restenosis. NK2 Homeobox 3 (Nkx2‐3), a critical member of Nkx family, is involved in tissue differentiation and organ development. However, the role of Nkx2‐3 in VSMCs proliferation and migration remains unknown. In this study, we used carotid balloon injury model and platelet‐derived growth factor‐BB (PDGF)‐treated VSMCs as in vivo and in vitro experimental models. EdU assay and CCK‐8 assay were used to detect cell proliferation. Migration was measured by scratch test. Hematoxylin and eosin staining and immunohistochemistry staining were used to evaluate the intimal hyperplasia. The autophagy level was detected by fluorescent mRFP‐GFP‐LC3 in vitro and by transmission electron microscopy in vivo. It was shown that Nkx2‐3 was upregulated both in balloon injured carotid arteries and PDGF‐stimulated VSMCs. Adenovirus‐mediated Nkx2‐3 overexpression inhibited intimal hyperplasia after balloon injury, and suppressed VSMCs proliferation and migration induced by PDGF. Conversely, silencing of Nkx2‐3 by small interfering RNA exaggerated proliferation and migration of VSMCs. Furthermore, we found that Nkx2‐3 enhanced autophagy level, while the autophagy inhibitor 3‐MA eliminated the inhibitory effect of Nkx2‐3 on VSMCs proliferation and migration both in vivo and in vitro. Moreover, Nkx2‐3 promoted autophagy in VSMCs by activating the AMP‐activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. These results demonstrated for the first time that Nkx2‐3 inhibited VSMCs proliferation and migration through AMPK/mTOR‐mediated autophagy.
- 30 April 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (11) , 7342-7355
Nkx2‐3 induces autophagy inhibiting proliferation and migration of vascular smooth muscle cells via AMPK/mTOR signaling pathway
Vascular remodeling and restenosis are common complications after percutaneous coronary intervention. Excessive proliferation and migration of vascular smooth muscle cells (VSMCs) play important roles in intimal hyperplasia‐induced vascular restenosis. NK2 Homeobox 3 (Nkx2‐3), a critical member of Nkx family, is involved in tissue differentiation and organ development. However, the role of Nkx2‐3 in VSMCs proliferation and migration remains unknown. In this study, we used carotid balloon injury model and platelet‐derived growth factor‐BB (PDGF)‐treated VSMCs as in vivo and in vitro experimental models. EdU assay and CCK‐8 assay were used to detect cell proliferation. Migration was measured by scratch test. Hematoxylin and eosin staining and immunohistochemistry staining were used to evaluate the intimal hyperplasia. The autophagy level was detected by fluorescent mRFP‐GFP‐LC3 in vitro and by transmission electron microscopy in vivo. It was shown that Nkx2‐3 was upregulated both in balloon injured carotid arteries and PDGF‐stimulated VSMCs. Adenovirus‐mediated Nkx2‐3 overexpression inhibited intimal hyperplasia after balloon injury, and suppressed VSMCs proliferation and migration induced by PDGF. Conversely, silencing of Nkx2‐3 by small interfering RNA exaggerated proliferation and migration of VSMCs. Furthermore, we found that Nkx2‐3 enhanced autophagy level, while the autophagy inhibitor 3‐MA eliminated the inhibitory effect of Nkx2‐3 on VSMCs proliferation and migration both in vivo and in vitro. Moreover, Nkx2‐3 promoted autophagy in VSMCs by activating the AMP‐activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. These results demonstrated for the first time that Nkx2‐3 inhibited VSMCs proliferation and migration through AMPK/mTOR‐mediated autophagy.